Shanghai Child and Adolescent Large-scale Eye Study -High Myopia Registration
Launched by SHANGHAI EYE DISEASE PREVENTION AND TREATMENT CENTER · Sep 10, 2018
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
1. introduction 1.1 Overview of myopia and high myopia Myopia is the most common eye disease in the world . Among them, the incidence and prevalence of myopia are highest in developed countries and regions in East and Southeast Asia. It is predicted that by 2050, global myopia patients would reach 5 billion, 1 billion of which were high myopia. In developed countries and regions in East and Southeast Asia, the prevalence of myopia in high school graduates is as high as 80% to 90%. A study in Taiwan showed that more than 80% of adolescents suffered from myopia when they graduated from high s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children and adolescents between the ages of 4 and 18 years old, SE ≤ -4 D under 5 years old, SE ≤ -6 D at 6-8 years old, SE ≤ -8 D over 9 years old;
- • No eye disease, good general condition, can cooperate with the examiner;
- • Obtaining the consent of the child and his/her guardian;
- • Long-term residence in this city, there is no plan to move out of this city in the short term.
- Exclusion Criteria:
- • Amblyopia (best corrected visual acuity (BCVA) less than 0.8 for children over 6 years old, BCVA less than 0.63 for children 6 years old and younger) and strabismus;
- • Secondary myopia, genetic disease or connective tissue-related myopia;
- • Moderate or severe ptosis;
- • Congenital cataract, glaucoma;
- • Other fundus diseases other than myopic related fundus lesions;
- • Intraocular or refractive surgery history;
- • The refractive medium is turbid, and it is impossible to take a clear fundus image;
- • Unable to cooperate with fundus image shooting and other examination;
- • Do not receive cycloplegia or have contraindications;
- • Poor overall condition, unable to follow up for a long time;
- • The child or the guardian refuses to participate in the research;
- • Other cases in which the researcher judges that it is not suitable for participation in the study.
About Shanghai Eye Disease Prevention And Treatment Center
The Shanghai Eye Disease Prevention and Treatment Center is a leading clinical research organization dedicated to advancing the understanding and treatment of ocular diseases. With a strong emphasis on innovation and patient-centered care, the center collaborates with various stakeholders, including academic institutions and healthcare providers, to conduct rigorous clinical trials. Its mission is to enhance eye health outcomes through evidence-based research, contributing to the global body of knowledge in ophthalmology. The center is committed to fostering a culture of excellence in clinical practices, ensuring the highest standards of safety and efficacy in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Xu Xian
Principal Investigator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials